Clinical trials: Neovascularization, Pathologic
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of…
- Trial name
- NCT00837330
- Testing
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Corneal Neovascularization
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
- Trial name
- NCT00512876
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center